Aperon Biosystems Corp.
This article was originally published in Start Up
Executive Summary
Aperon Biosystems Corp. wants to make monitoring of nitric oxide-a reliable marker of airway inflammation--as routine for asthma patients as glucose checks are for diabetics. It is developing a low cost, noninvasive NO biosensor suitable for use at the point of care and at home for asthma self management. The company believes that regular monitoring with its device will give patients the feedback they need to better control their symptoms.
You may also be interested in...
Start-Up News October 2006
Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.
NYSCC Suppliers Day Features Biotech, Sun Care, Antimicrobials Among Ingredient Innovations
DSM’s Quali Vitamin B12 and Biosyntia’s sustainably sourced biotin were among biotech-based ingredients at the New York Society of Cosmetic Chemists’ Suppliers Day in New York. Other showcased products included antimicrobials, microbiome ingredients, and zinc oxide filters for sun protection.
FDA Grants EUA To First OTC Test That Detects COVID-19, Flu, RSV
The US agency has issued an emergency use authorization to Labcorp for its over-the-counter test that detects COVID-19, flu and respiratory syncytial virus.